한글목차

세계 HIV 진단 및 치료제 시장 규모는 2023년 304억 달러에서 예측 기간 동안 5.3%의 CAGR을 나타내고, 2028년 말에는 393억 달러 규모로 성장할 것으로 예상됩니다.

ARV 약물 카테고리별로 살펴보면, 단일정제(STR)/고정용량 복합제(FDC) 약물 부문은 2023년 11.3억 달러에서 2028년 말 14.9억 달러로 연평균 5.8%의 성장률을 보이며 2028년 말 14.9억 달러 규모로 성장할 것으로 예상됩니다. 또한, 뉴클레오티드 역전사효소 억제제(NRTI) 부문은 2023년 89억 달러에서 4.4%의 CAGR로 2028년 말에는 110억 달러 규모로 성장할 것으로 예측됩니다.

세계 HIV 진단 및 치료제 시장을 조사했으며, 시장 및 기술 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 기술 및 특허 동향, ESG 동향, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 요약 및 하이라이트

제3장 시장 및 기술 배경

• 인간 면역 결핍 바이러스(HIV) 개요
• 보고서 개요
• 질환의 예후
• 증상
• 치료법
• HIV의 타임라인과 마일스톤
• HIV의 수명주기 : 치료와 작용기전
• HIV 예방
• 노출 전 예방 내복(PrEP)
• 노출 후 예방 내복(PEP)
• 약제 내성
• 복약 준수
• WHO의 대처

제4장 세계 산업 동향

• 세계의 HIV 감염 동향
• 지역 계발 프로그램
• 신규 치료법 개발
• 민관 파트너십
• 환자 수명 연장에 따른 HIV 환자 병존 질환 증가
• HIV 박멸 세계 프로그램
• 모자 간염 예방
• 과제
• 이환 리스크 과소평가
• STD에 관련된 사회적 편견
• 고액의 치료비

제5장 시장 내역 : HIV 치료제별

• 세계 시장 예측
• 지역 시장
• 북미
• 시장 분석·예측
• 역학
• HIV 검사·추천 사항
• 북미 시장의 관련 규제
• 유럽의 HIV 치료제 시장
• 시장 분석·예측
• 역학
• HIV 검사·추천 사항
• 유럽의 HIV 시장에 영향을 미치는 규제
• 아시아태평양의 HIV 치료제 시장
• 동남아시아 지역
• 서태평양 지역
• 예방 및 스크리닝 프로그램
• 아시아태평양의 HIV 시장 규제
• 제네릭 제조업체 시장에 대한 영향
• 시장 분석·예측
• 기타 지역의 HIV 치료제 시장
• 아프리카
• HIV 시장에 대한 세계의 투자

제6장 HIV 시장 : ARV 약제 카테고리별

• 개요
• 치료 타임라인
• 제1 선택 치료 계획
• 제2 선택 치료 계획
• 제3 선택 치료 계획
• 시장 개요 : 의약품 카테고리별
• 뉴클레오티드/뉴클레오티드 역전사효소 억제제(NRTI)
• 프로테아제 억제제(PI)
• 단일정제 요법(STR)/고정용량 복합제(FDC) 약물
• 인테그라제 가닥 전달 억제제(INSTI)
• 비뉴클레오티드 역전사효소 억제제(NNRTI)
• 침입 저해제

제7장 신기술

• 개요
• 분자진단
• 차세대 시퀀싱(NGS)
• POC(Point of Care) 검사
• 인공지능(AI)
• 기타

제8장 HIV 진단 시장 평가

• HIV 진단 시장 : 검사 유형별
• HIV 검사 진화
• 항원 및 항체에 근거한 검사
• 향후 전망
• CD4 테스트
• 바이러스 부하 테스트
• HIV 진단 제품 개요 : 검사 유형별
• CD4 검사 제품
• 바이러스 부하 검사 제품

제9장 특허

제10장 경쟁 구도

• 인수합병(M&A)·제휴

제11장 기업 개요

• ABBOTT
• ASTRAZENECA
• B. BRAUN SE
• BECTON, DICKINSON AND COMPANY
• BIOCON
• BIO-RAD LABORATORIES INC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• DANAHER CORP.
• DEXCOM INC.
• INSULET CORP.
• JOHNSON & JOHNSON SERVICES INC.
• LIFESCAN IP HOLDINGS LLC
• LILLY
• MEDTRONIC
• MERCK & CO. INC.
• NOVA BIOMEDICAL
• NOVARTIS AG
• NOVO NORDISK A/S
• QIAGEN N.V.
• ROCHE(F. HOFFMANN-LA ROCHE LTD.)
• SANOFI
• SIEMENS HEALTHINEERS AG
• TERUMO CORP.
• THERMO FISHER SCIENTIFIC INC.
• YPSOMED AG

영문목차

Highlights:

The global market for HIV diagnostics and therapeutics is expected to increase from $30.4 billion in 2023 to $39.3 billion by the end of 2028, with compound annual growth rate (CAGR) of 5.3% during the forecast period of 2023-2028.

Single-tablet regimen FDC market for HIV diagnostics and therapeutics is expected to increase from $11.3 billion in 2023 to $14.9 billion by the end of 2028, at a CAGR of 5.8 during the forecast period of 2023-2028.

Nucleoside reverse transcriptase inhibitors market for HIV diagnostics and therapeutics is expected to increase from $8.9 billion in 2023 to $11.0 billion by the end of 2028, at a CAGR of 4.4% during the forecast period of 2023-2028.

Report Scope:

This report organizes information from diverse sources into sections such as an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements, and patents. The scope of this report includes an overview of the global market scenario for the diagnosis and treatment of HIV, with base year data from 2022, estimations for 2023 and forecasts for 2028 that are derived using projections of CAGR during the forecast period. Market value data is provided at global, regional, and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

The report forecasts the global market for HIV therapeutics by drug class. It discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.

Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests, and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.

A detailed analysis illustrating market dynamics and market structure is incorporated into the report. A Porter's Five Forces analysis and the supply and distribution chain are discussed in detail to provide an in-depth understanding of this market. The report covers the current regulations and guidelines for diagnostics and therapeutics for HIV, and it provides a survey of the top market players, detailing their business operations, segment focus, revenue, and strategy analysis. The report also features a market share analysis of these leading players, including information about product launches and pipeline products.

In terms of geography, the report analyzes the market across the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). Key countries like the U.S., Canada, Mexico, Germany, France, UK, Italy, China, India and Japan are given special focus due to the high concentration of HIV diagnostics and therapeutics manufacturing companies and contract manufacturing organizations located in these areas.

The base year for the market data in this report is 2022, historical data is provided for 2020 and forecast data is given for 2028. Historical, base year and forecast data are provided for each market segment of the report.

Report Includes:

• 27 data tables and 41 additional tables
• An overview of the global markets for diagnostics and therapeutics for HIV
• An estimate of the market's size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Quantification of the market potential of diagnostics and therapeutics for HIV by drug category, diagnostic test type, and region
• Coverage of HIV timeline and milestones, HIV life cycle, its treatment and mechanism of action, and description of HIV prophylaxis
• Evaluation of market dynamics such as drivers and restraints, current industry trends and patterns, and an assessment of the cost implications for treatments in many countries
• Information on regional awareness programs, WHO initiatives and development of novel therapies, and discussion on rising comorbidities in HIV patients and social stigma associated with STDs
• Coverage of ongoing research and predictions of the market's future direction
• Insights into the regulatory scenario for the U.S., Europe and Japan, to provide an overview of the regulations for new drug launches and diagnostic kits
• Descriptions of the competitive landscape, product mapping, the strategic initiatives of the leading companies, including their R&D activities
• Profiles of the key companies, including Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories Inc., and Danaher Corp.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• What's New in This Update?
• Scope of Report
• Information Sources and Methodology
• Secondary Research
• Primary Research
• Research Methodology
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Overview
• Market Outlook

Chapter 3 Market and Technology Background

• Overview of Human Immunodeficiency Virus (HIV)
• Report Overview
• Disease Prognosis
• Symptoms
• Treatments
• HIV Timeline and Milestones
• HIV Life Cycle: Treatment and Mechanism of Action
• HIV Prophylaxis
• Pre-exposure Prophylaxis (PrEP)
• Post-exposure Prophylaxis (PEP)
• Drug Resistance
• Medication Adherence
• WHO Initiatives

Chapter 4 Global Industry Trends

• Trends in Global HIV Transmission
• Regional Awareness Programs
• Development of Novel Therapies
• Public-Private Partnerships
• Rising Comorbidities in HIV Patients with an Increase in the Longevity of Patients
• Global Programs to Counter HIV
• Preventing Transmission from Mother to Child
• Challenges
• Underestimating the Risk of Contracting the Disease
• Social Stigma Associated with STDs
• High Cost of Treatment

Chapter 5 Market Breakdown by HIV Therapeutic

• Global Market Forecast for HIV Therapeutics
• Regional Markets for HIV Therapeutics
• North America
• Market Analysis and Forecast
• Epidemiology
• HIV Testing and Recommendations
• Regulation of the North American Market for HIV Therapeutics
• European Market for HIV Therapeutics
• Market Analysis and Forecast
• Epidemiology
• HIV Testing and Recommendations
• Regulations Impacting the European HIV Market
• Asia-Pacific Market for HIV Therapeutics
• Southeast Asian Regions
• Western Pacific Regions
• Prevention and Screening Programs
• Regulation of the Asia-Pacific HIV Market
• Market Impact of Generic Manufacturers
• Market Analysis and Forecast
• Rest of the World (RoW) Market for HIV Therapeutics
• African Region
• Global Investments in the HIV Market

Chapter 6 HIV Market by ARV Drug Category

• Overview
• Timeline of Therapies
• First-Line Treatment Regimen
• Second-Line Treatment Regimen
• Third-Line/Salvage Treatment Regimen
• Market Overview by Drug Category
• Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
• Protease Inhibitors (PIs)
• Single-Tablet Regimen (STR)/Fixed-Dose Combination (FDC) Drugs
• Integrase Strand Transfer Inhibitors (INSTI)
• Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)
• Entry Inhibitors

Chapter 7 Emerging Technologies

• Overview
• Molecular Diagnostics
• Next-Generation Sequencing (NGS)
• Point-of-Care Testing
• Artificial Intelligence (AI)
• Other Emerging Techniques

Chapter 8 Evaluation of Market for HIV Diagnostics

• Market for HIV Diagnostics by Test Type
• Evolution of HIV Tests
• Antigen- and Antibody-Based Tests
• Future Perspective
• CD4 Testing
• Viral Load Testing
• HIV Diagnostic Product Profiles by Test Type
• CD4 Testing Products
• Viral Load Testing Products

Chapter 9 Patents

• Overview

Chapter 10 Competitive Landscape

• Mergers, Acquisitions and Collaborations

Chapter 11 Company Profiles

• ABBOTT
• ASTRAZENECA
• B. BRAUN SE
• BECTON, DICKINSON AND COMPANY
• BIOCON
• BIO-RAD LABORATORIES INC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• DANAHER CORP.
• DEXCOM INC.
• INSULET CORP.
• JOHNSON & JOHNSON SERVICES INC.
• LIFESCAN IP HOLDINGS LLC
• LILLY
• MEDTRONIC
• MERCK & CO. INC.
• NOVA BIOMEDICAL
• NOVARTIS AG
• NOVO NORDISK A/S
• QIAGEN N.V.
• ROCHE (F. HOFFMANN-LA ROCHE LTD.)
• SANOFI
• SIEMENS HEALTHINEERS AG
• TERUMO CORP.
• THERMO FISHER SCIENTIFIC INC.
• YPSOMED AG